Skip to main content

Evaxion Biotech A/S (EVAX)

NASDAQ: EVAX · IEX Real-Time Price · USD
9.99
+0.44 (4.61%)
After-hours:Sep 24, 2021 7:15 PM EDT
9.55
0.74 (8.40%)
At close: Sep 24, 4:00 PM
Market Cap183.35M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out19.20M
EPS (ttm)-1.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume75,645
Open8.83
Previous Close8.81
Day's Range8.71 - 9.55
52-Week Range5.16 - 10.34
Betan/a
AnalystsStrong Buy
Price Target19.00 (+99.0%)
Est. Earnings DateNov 9, 2021

About EVAX

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-s...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees35
Stock ExchangeNASDAQ
Ticker SymbolEVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 98.95% from the latest price.

Price Target
$19.00
(98.95% upside)
Analyst Consensus: Strong Buy

News

Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer

COPENHAGEN, Denmark, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

5 days ago - GlobeNewsWire

Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update

COPENHAGEN, Denmark, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-drive...

1 month ago - GlobeNewsWire

REE Automotive Announces Strategic Collaboration With EVAX: What You Need To Know

REE Automotive announced Tuesday it has struck an agreement for a strategic collaboration with JB Poindexter & Co.'s newest business unit EVAX for the purpose of developing commercial electric vehicles....

2 months ago - Benzinga

Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

COPENHAGEN, Denmark, July 08, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the li...

2 months ago - GlobeNewsWire

Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8

COPENHAGEN, Denmark, July 07, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

2 months ago - GlobeNewsWire

Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming

COPENHAGEN, Denmark, June 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

3 months ago - GlobeNewsWire

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion's AI-powered Vaccine Platform RAVEN for the Des...

COPENHAGEN, Denmark, June 03, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company developing AI-driven immunotherapies and vaccines to improve the lives of pati...

3 months ago - GlobeNewsWire

Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update

COPENHAGEN, Denmark, May 13, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven...

4 months ago - GlobeNewsWire

Evaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13

COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve t...

4 months ago - GlobeNewsWire

Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy

COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driv...

5 months ago - GlobeNewsWire

Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

COPENHAGEN, Denmark, April 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

5 months ago - GlobeNewsWire

Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6

COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

5 months ago - GlobeNewsWire

Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports

COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...

6 months ago - GlobeNewsWire

Evaxion Biotech Opens New Office and Laboratories to Support Future Growth

COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve ...

7 months ago - GlobeNewsWire

Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares

COPENHAGEN, Denmark, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patien...

7 months ago - GlobeNewsWire